Meurice J C, Marc I, Sériès F
Unité de Recherche, Hôpital Laval, Université Laval, Québec, Canada.
Am J Respir Crit Care Med. 1996 Feb;153(2):794-8. doi: 10.1164/ajrccm.153.2.8564134.
The auto-CPAP (Morphée Plus) is characterized by its ability to modify the positive-pressure level applied during the night for the presence or absence of sleep-induced respiratory disorders. The aim of the study was to compare the efficacy of this new mode of CPAP therapy with that of conventional constant-CPAP in the treatment of sleep apnea/hypopnea syndrome (SAHS). Sixteen patients with SAHS were randomly allocated to two groups that were paired for age, apnea/hypopnea index, and mean sleep latency. In the auto-CPAP group, the pressure level could change within fixed limits in both directions (+2 to -4 cm H2O) of the previously determined effective pressure level (Peff). In the constant-CPAP group, patients used the same apparatus (Morphée Plus) in a constant mode at Peff level. At the beginning of the study, the Peff level was determined during a polysomnographic recording. Day-time vigilance was measured subjectively by a standardized questionnaire and objectively by the maintenance of wakefulness test (MWT); Trailmaking tests (TMT) were used to evaluate cognitive functions. After 3 wk of home CPAP therapy, a control sleep study was done with the CPAP machine used in the protocol, and daytime vigilance and cognitive function tests were obtained. Baseline sleep and nocturnal breathing disorders characteristics did not differ between the two groups, and daytime vigilance and cognitive function abnormalities were similarily altered. In both groups, the apnea/hypopnea index was within normal range at the final CPAP sleep study. In the auto-CPAP group, 49.3 +/- 14.9% (mean +/- SD) of home treatment time was spent at a pressure < or = Peff. Home amount of use estimated by the number of sleeping hours with a positive pressure applied was 6.5 +/- 1.0 h in the auto-CPAP group and 5.1 +/- 1.1 h in the constant-CPAP group (p = 0.02). During the control CPAP sleep study, the positive pressure level was significantly lower during Stage III-IV than during the other sleep stages (p = 0.004). The improvement in the MWT and the TMT observed with CPAP therapy was identical in both groups. We conclude that (1) the amount of use during CPAP treatment is higher with auto-CPAP than with constant-CPAP, and (2) Morphée+auto-CPAP is an efficient as conventional CPAP in correcting nocturnal breathing disorders, daytime sleepiness, and cognitive impairment in SAHS.
自动持续气道正压通气设备(Morphée Plus)的特点是能够根据睡眠期间是否存在呼吸紊乱来调整夜间施加的正压水平。本研究的目的是比较这种新型持续气道正压通气治疗模式与传统固定持续气道正压通气在治疗睡眠呼吸暂停/低通气综合征(SAHS)方面的疗效。16例SAHS患者被随机分为两组,两组在年龄、呼吸暂停/低通气指数和平均睡眠潜伏期方面进行了配对。在自动持续气道正压通气组中,压力水平可在先前确定的有效压力水平(Peff)的两个方向(+2至 -4 cm H2O)的固定范围内变化。在固定持续气道正压通气组中,患者使用相同的设备(Morphée Plus)以Peff水平的固定模式进行治疗。在研究开始时,通过多导睡眠图记录确定Peff水平。白天警觉性通过标准化问卷进行主观测量,并通过清醒维持测试(MWT)进行客观测量;使用连线测验(TMT)评估认知功能。经过3周的家庭持续气道正压通气治疗后,使用方案中规定的持续气道正压通气设备进行对照睡眠研究,并获得白天警觉性和认知功能测试结果。两组之间的基线睡眠和夜间呼吸障碍特征没有差异,白天警觉性和认知功能异常的改变情况相似。在两组中,在最终的持续气道正压通气睡眠研究中,呼吸暂停/低通气指数均在正常范围内。在自动持续气道正压通气组中,49.3±14.9%(平均值±标准差)的家庭治疗时间是在压力≤Peff的情况下度过的。通过施加正压的睡眠时间估计的家庭使用量,自动持续气道正压通气组为6.5±1.0小时,固定持续气道正压通气组为5.1±1.1小时(p = 0.02)。在对照持续气道正压通气睡眠研究期间,Ⅲ-Ⅳ期的正压水平明显低于其他睡眠阶段(p = 0.004)。两组中观察到的持续气道正压通气治疗对MWT和TMT的改善情况相同。我们得出结论:(1)自动持续气道正压通气治疗期间的使用量高于固定持续气道正压通气;(2)Morphée +自动持续气道正压通气在纠正SAHS患者的夜间呼吸障碍、白天嗜睡和认知障碍方面与传统持续气道正压通气一样有效。